

Comparing lateral flow testing with a rapid RT-PCR method for SARS-CoV-2 detection in the UK

Short title: Comparing lateral flow with RT-PCR for SARS-CoV-2 detection

Andrew Taylor¹

Ronan Calvez¹

Mark Atkins¹

*Colin G Fink^{1,2}

¹Micropathology Ltd, University of Warwick Science Park, Venture Centre, Sir William Lyons Road,
Coventry, CV4 7EZ, UK.

²University of Warwick, Coventry, West Midlands, CV4 7AL, UK.

*colinfink@micropathology.com

1 **Abstract**

2

3 In late 2019, SARS-CoV-2 emerged in the Wuhan province of China. Rapid global spread led to the
4 Covid-19 pandemic. Rapid and accurate detection of SARS-CoV-2 has become a vitally important
5 tool in controlling the spread of the virus. Lateral flow devices (LFDs) offer the potential advantage
6 of speed and on-site testing. The sensitivity of these devices compared to the gold standard RT-PCR
7 has been questioned. We compared the performance of the Innova lateral flow kit, recommended
8 by the UK government, with our rapid in-house RT-PCR protocol using stored positive patient
9 samples. The LFD device was found to be 6,000-10,000 times less sensitive than RT-PCR for the
10 detection of SARS-CoV-2. Overall, the LFD detected 46.2% of the positives detected by RT-PCR. 50%
11 of the LFD results were observed to be weak positives, only visible after careful examination by
12 experienced laboratory staff. At lower viral loads, such as 10,000-100,000 RNA copies/ml, the LFD
13 detected 22.2% of positives. In addition, two strong positives (3 and 1.5 million RNA copies/ml)
14 were not detected by the LFD. The argument for use of LFD kits, despite their lack of sensitivity, is
15 that they detect infectious virus and hence contagious individuals. At present, there is a lack of
16 scientific evidence supporting this claim. The LFD used in the UK fails to identify individuals with
17 considerable viral loads and has been subject to a class I recall by the US FDA but is still approved
18 and recommended for use by the UK government. We believe that using LFD testing for assessing
19 SARS-CoV-2 infection risk is a strategy which has risks that outweigh any benefits.

20

21

22

23

24

25

26

27 Introduction

28

29 In late 2019, a novel coronavirus emerged in the Wuhan province of China. This virus was
30 designated severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and rapid global spread
31 lead to the Covid-19 pandemic. The symptoms of infection vary between individuals but the most
32 common symptoms are fever, dry cough, headache, fatigue, anosmia and diarrhoea^{1,2}. As of 13th
33 June 2021, there have been 175 million global cases with 3.79 million deaths³. The UK has been
34 badly affected with 4.55 million cases and the highest official death toll in Europe (>127, 000). The
35 devastating nature of this pandemic facilitated the need for high-throughput and accurate diagnostic
36 methods. RT-PCR protocols for the detection of SARS-CoV-2 RNA were published very early in the
37 pandemic with the first publication detailing probe-based RT-PCR assays targeting E, N and RdRp
38 genes⁴. Shortly after this, the US CDC published three assays (all probe-based RT-PCR assays) which
39 target three separate regions of the N gene⁵. These assays were given the names N1, N2 and N3
40 although the N3 assay was later removed as it was deemed unreliable. Many of these published
41 assays have been developed as commercial kits and are used globally for the detection of SARS-CoV-
42 2 RNA. We developed a highly sensitive, rapid, UKAS accredited in-house RT-PCR assay utilising the
43 N1 assay published by the CDC⁶. RNA is prepared using a rapid heat treatment method, removing
44 the need for time-consuming and expensive nucleic acid extraction kits⁶.
45 RT-PCR has the advantage of being the most sensitive diagnostic technique available and is regarded
46 as the gold standard for SARS-CoV-2 detection. As the pandemic progressed, the possibility of using
47 rapid, point of care devices such as lateral flow devices (LFDs), has been further investigated. Such
48 kits target viral proteins and thus claim to detect live virus and hence infectious individuals⁷. They
49 claim to offer the advantage that results can be obtained in as little as 30 minutes reportedly
50 without the need for skilled staff or laboratory processing. However, there have been questions
51 about the sensitivity of such kits, particularly when compared to RT-PCR⁸⁻¹¹.

52 We retrospectively compared the UK government supplied Innova LFD with RT-PCR using a range of
53 samples that had previously tested as SARS-CoV-2 positive using our diagnostic PCR service. Using
54 digital droplet PCR to calibrate clinical samples, we were able to directly compare PCR (in terms of
55 RNA copies/ml) with the LFD device currently recommended for use in the UK for assessing infection
56 risk of individuals in schools, universities, hospitals and for the general public.

57

58 **Methods**

59

60 *Patient samples*

61 Initially, 62 stored swab samples were selected for testing. This comprised 52 known PCR positive
62 samples (original Ct value 18.9-36.5) and 10 negatives. Samples were previously tested as part of
63 our routine diagnostic service and had been stored at -20°C for up to 3 months. Samples consisted of
64 either dry swabs which were resuspended in 500µl of 0.1% Igepal CA-630 (Sigma Aldrich) or swabs in
65 UTM. Following the emergence of the delta variant eight additional samples, which were confirmed
66 delta variants, were also tested.

67

68 *RT-PCR*

69 Samples were prepared for RT-PCR using a rapid heat-treatment method⁶. This involves heating
70 samples to 95°C for 5 minutes and cooling to 4°C. 40µl of sample was heat treated and 10µl used for
71 PCR (25µl reaction volume). RT-PCR was then carried out in triplicate using Fast 1-Step RT-qPCR
72 (Meridian Bioscience)⁶. To further explore comparative sensitivity of RT-PCR and LFD, a strongly
73 positive sample (sample 29) was quantified using droplet digital (dd) PCR (QX200, Bio-Rad) and
74 serially diluted from 2.2 million to 220 RNA copies/ml in 0.1% Igepal CA-630. Triplicate PCR was
75 carried out as described above.

76 The lower limit of detection (LLoD) of this method was determined by Probit regression analysis
77 (MedCalc, MedCalc Software Ltd) using a diluted RNA extract which was quantified by ddPCR.

78 *Lateral flow*

79 Lateral flow kits used for SARS-CoV-2 testing in the UK (Innova rapid antigen test, manufactured by
80 Xiamen Biotime Biotechnology) were directly compared to the RT-PCR method. Instructions
81 provided with the kit state that 2 drops of extraction buffer should be applied to an LFD strip.
82 Therefore, the volume of 2 drops of buffer from an extraction tube was measured using a calibrated
83 pipette and found to be 50 μ l. To standardise all LFD tests, this volume of sample was added to each
84 LFD using a pipette. Frozen patient samples were thawed and 40 μ l mixed with 160 μ l of LFD
85 extraction buffer by vortexing. From this, 50 μ l was applied to LFD strips in triplicate. Using this
86 method, the same equivalent volume of patient sample (10 μ l) was tested on each LFD compared to
87 each single RT-PCR reaction allowing direct comparison of the two procedures under standardised
88 conditions. Kits were used following the manufacturers' instructions and results scored
89 independently by 2 experienced laboratory staff in standardised light conditions. The LLoD was
90 determined as above using Probit regression analysis. The dilution series of sample 29 (described
91 above) was also tested in triplicate on LFDs.

92

93 *Statistical analysis*

94 Probit regression (MedCalc) was used to determine the LLoD (with 95% confidence interval) of both
95 methods. These were calculated using either the Ct values or the viral load (in RNA copies/mL) as
96 measured by ddPCR. The correlation between viral load and LFD result was calculated in Excel by
97 first converting the LFD results into a score of 0-3 reflecting the number of replicates with a positive
98 result. The Pearson correlation value (r) was then calculated.

99

100 *Ethical statement*

101 This study was performed at Micropathology Ltd (University of Warwick Science Park, Coventry, UK)
102 in April – June 2021. Patient samples were anonymised and were not considered Human Subjects
103 Research due to the quality improvement and public health intent of the work. This study was

104 reviewed and approved by the Micropathology Ltd Ethics Committee Review Board composed of
105 Professor Sheila Crispin (MA, VetMB, DVA, DVOPhthal, DipEVCO, FRCVS), Professor Christopher
106 Dowson (BSc, PhD), Rt Hon Countess of Mar, Most Rev Dr Gordon Mursell (MA, Hon DD) and William
107 NH Taylor (BTech)). No additional consent was necessary.

108

109 **Results**

110

111 *Sample set*


112 Approximately equal numbers of samples from male and female patients were tested (Table S1).
113 The age of patients ranged from 4 to 92 and the mean Ct value from the original PCR results was 30.
114 No samples with an original Ct value >37 (<3000 RNA copies/ml) were tested.

115

116 *Comparing RT-PCR with LFD*

117 Summarising the data for the 62 samples tested, all ten of the previous PCR negatives were negative
118 on all three replicates of PCR and LFD (Fig. 1). Of the 52 previously positive samples, 51 were
119 positive in all 3 PCR replicates and one sample was positive in 2 out of 3 replicates. Of these 52, only
120 24 (46.2%) returned positive LFD results in at least 2 out of 3 replicates. Considering viral load,
121 samples with a viral load of > 1 million copies/ml resulted in an 85.6% detection rate on LFD.
122 Surprisingly, two samples in this range (3 million and 1.5 million copies per ml) were negative in all 3
123 LFD replicates. Preliminary sequencing data (not shown) suggests that both of these samples
124 contain the Alpha variant, the dominant variant at the time the samples were taken. In the range of
125 100,000 – 1 million copies per ml, 46.7% of the samples were positive in at least 2 of the 3 replicate
126 LFD tests. The sensitivity of LFD was very limited in the range of 10,000-10000 RNA copies/ml
127 (22.2%) and even lower at <10,000 copies/ml (15.4%). A statistically significant correlation between
128 Ct value (or log viral load) and LFD result was observed ($r = 0.59$, $P < 0.001$).

n	Viral load (copies/ml)	PCR positive (%)	LFD positive (%)
15	>1 million	100	85.6
15	100,000-1million	100	46.7
9	10,000-100,000	100	22.2
13	<10,000	100	15.4
52	OVERALL	100	46.2
	Ct Value		
19	<30	100	73.7
20	30-35	100	40.0
13	>35	100	15.4
52	OVERALL	100	46.2
10	Negative	0	0



129


130 **Fig. 1:** Comparing LFD with RT-PCR. Samples which were positive in at least 2 out of the 3 replicates were
 131 classified as positive. A green data point represents a sample where at least 2 out of 3 replicate tests were
 132 positive. A red data point indicates a sample where 0 or 1 of the 3 replicates were positive. Of the 52 positive
 133 samples tested, 51 were positive in all 3 RT-PCR replicates. One sample was positive in 2 out of 3 RT-PCR
 134 replicates. Photographs of the LFD device show examples of positive (top) and negative (bottom) test results.
 135 The 95% confidence interval was calculated using a Probit regression analysis (Fig. 2).

136 *LOD of LFD and RT-PCR*

137 The Probit analysis (Fig. 2a) revealed that the LOD of the RT-PCR assay, when run as a duplex assay
138 with an internal control, is 743 copies/ml (95% confidence interval 508-1,559 RNA copies/ml; $P <$
139 0.0001). The sensitivity can be further improved to 681 copies/ml by doubling the reaction volumes
140 (95% confidence interval 540-822 RNA copies/ml; $P <$ 0.0001; data not shown). Using the data
141 summarised in Fig. 1, we performed a Probit analysis (Fig. 2b) to determine the LLoD of the LFD
142 devices (expressed in terms of RNA copies/ml for direct comparison with RT-PCR). The LLoD was
143 found to be 4.35 million copies/ml (95% confidence interval 2.75-12.0 million copies/ml, $P <$ 0.0001),
144 suggesting that the LFD devices were ~6,000 times less sensitive than RT-PCR.

145 To further explore the sensitivity of LFD devices, a dilution series of a strongly positive sample (22
146 million copies/ml) was tested. A strong correlation between viral load (digital PCR) and Ct value (RT-
147 PCR) was observed ($r = -0.998$, $P <$ 0.001, Fig. 3). All LFD tests were negative below 2.2 million
148 copies/ml although PCR was successful down to 220 copies/ml. This indicates that the PCR test used
149 is at least 10,000 times more sensitive than LFD, which is consistent with the data obtained above,
150 using undiluted samples.

151



152

153 **Fig. 2:** Evaluation of the lower limit of detection of the RT-PCR assay (a) and the Innova rapid antigen LFD (b)


154 expressed as RNA copies per ml. Probit regression was used to calculate the LLoD of the LFDs using the data

155 summarised in Fig. 1 compared to RT-PCR when multiplexed with an internal control (potato virus Y, PVY).

156

157

158




159

160 **Fig. 3:** Correlating Ct value (RT-PCR) with viral load (digital PCR). Results of LFD tests are shown for each
161 dilution. The 95% confidence intervals were calculated based on the Probit analysis (Fig. 2).

162

163 Ct values of all SARS-CoV-2-positive samples tested as part of a diagnostic service from 1st – 31st Jan
164 2021 were analysed (Fig. 4). The mean Ct value was 32.7 (range 19.5 – 41.9). As part of this
165 diagnostics service, all samples with a Ct value greater than 39 were re-extracted and the PCR
166 repeated for confirmation. Based on the 95% confidence interval obtained from the Probit analysis,
167 LFD testing would only have detected 104 out of 501 positives (20.8%).



168

169 **Fig. 4:** Ct values obtained from positive patient samples tested from 1st – 31st January 2021. 95% confidence
170 intervals were calculated using Probit analyses.

171

172 *Detection of the delta variant*

173 Due to the rapid spread of the delta variant in the UK, eight samples which were confirmed to
174 contain the delta variant were tested by LFD and PCR. The results were comparable with the data
175 described above (Fig. 1). Samples with a Ct value of >30 were not detected by LFD (Table 1).
176 Samples with a Ct value of 26-30 were detected but scored as very weak.

177

178

179

180

181

182

183

184 **Table 1:** Testing the Innova LFD kit against delta variants of SARS-CoV-2. The image illustrates a
185 'weak positive' LFD result. SEM is the standard error of the mean based on 3 replicates.

Sample number	Original Ct value	LFD positive (out of 3)	LFD comments	RT-PCR Ct mean	Ct SEM	Viral load (cp/ml)
63	28.3	3	Very weak	29.6	0.095	765,633
64	25.0	3	Weak	26.5	0.075	7,982,706
65	21.1	3		22.3	0.095	192,679,428
66	36.8	0		36.7	0.439	3,530
67	32.2	0		33.1	0.328	57,215
68	26.2	3	Weak	26.5	0.111	7,922,565
69	18.1	3		18.5	0.027	3,489,133,920
70	19.0	3		21.4	0.171	395,223,450



186

187

188

189

190 Discussion

191 The UK government has been promoting the use of Innova LFD tests for rapid screening and home
192 testing to identify individuals infected with SARS-CoV-2. Data published by the Department of
193 Health and Social Care suggests that such tests have a high level of clinical specificity and thus a low
194 rate of false positives¹². The figures quoted are up to 100% specificity but the sensitivity of LFD tests
195 is somewhat overlooked. Government data from multiple testing sites shows a sensitivity of 37.4 –
196 57.4% when compared to PCR (viral load of samples not specified). Our data is in agreement with
197 these figures, using 52 positive patient samples we found a sensitivity of 46.2%. In reality, this
198 means that LFD devices detect less than half of the positives detected by PCR. However, when

199 considering the range of positives detected in our laboratory in a calendar month, the sensitivity of
200 LFD is likely to be much lower – a figure of 20.8% was calculated based on a 95% confidence interval.
201 An argument supporting the lack of sensitivity of LFD is that they are sufficient to detect ‘live’ virus
202 as shown by some cell culture experiments^{7,13,14}. The theory is that they should identify patients
203 who are contagious. It is not clear whether all of the positive patients tested by our laboratory
204 would be contagious and present a transmission risk. However, it is clear that the virus was present
205 within their respiratory tract as determined by the presence of RNA. Whilst a proportion of these
206 patients may be carrying residual/non-functional RNA or RNA coated in antibodies, it is likely that
207 some patients with a low viral load are at an early stage of infection, before symptom presentation.
208 Data published by Public Health England clearly shows that samples with Ct values of 32.5 can
209 contain live virus (1.2 PFU/ml) whilst detection by LFD is very poor in samples above Ct 28.5 (40
210 PFU/ml)¹⁵. In a separate study, also by Public Health England, it was shown that viable SARS-CoV-2
211 virus can be cultured from samples with Ct values >35¹⁶. Therefore, there is no general consensus as
212 to the relationship between viral load and infectiousness. We diluted a strong positive sample which
213 was positive on PCR and LFD (assumed to be live virus). When diluted 10-fold, the LFD result was
214 still positive but was negative when diluted 100-fold (220,000 copies/ml). RT-PCR remained positive
215 down to 220 copies/ml. Any correlation between detection of live virus and LFD positive is unproven
216 and LFD devices simply lack sensitivity to detect SARS-CoV-2 reproducibly.
217 It has been noted by others that Ct values only provide a guide on viral load and there is no
218 consensus on a Ct value which corresponds to infectiousness^{7,17}. Therefore, we used digital PCR to
219 correlate Ct values with viral loads. Government LFD testing data used samples with unspecified
220 viral loads¹². Previous data tested samples ranging from <1000 ->1 million copies/ml¹⁵. However, it
221 is not clear how these viral loads were calculated. The authors quote a Ct value of 25.5
222 corresponding to 100,000 copies/ml although, using our in-house assay, a Ct value of 25.5 was
223 equivalent to 17 million copies/ml.

224 The LFD tested here failed to detect SARS-CoV-2 in samples with viral loads of 3 million and 1.5
225 million copies/ml. This observation was also noted during large scale community testing in Liverpool
226 where LFD sensitivity was only 67% in samples with a Ct value $<25^{18}$. Furthermore, the studies cited
227 above used cell culture experiments to test for live virus and infer infectivity of a patient on this
228 basis^{7,13,14}. This data should be interpreted with caution; epidemiological data from Switzerland
229 showed that outbreaks occurred in areas where the first three cases had viral loads of $<100,000$
230 copies/ml¹⁹. Such cases would be missed by LFD testing and therefore transmission of the virus
231 could follow. A patient tested at our laboratory was initially positive for SARS-CoV-2 during routine
232 screening (Ct 38). He was put into isolation and started developing Covid symptoms two days later
233 with concurrent increase in viral load. This shows the critical importance of detecting low levels of
234 SARS-CoV-2 RNA in order to isolate patients. This initial sample would have been undetected using
235 an LFD.

236 The overall sensitivity of the LFD device, based on the samples tested here, was 46.2%. However, it
237 should be noted that 50% of the positive LFD tests (12/24) produced a very faint positive result (see
238 image in Table 1) across all replicates. These were scored as positive by two experienced laboratory
239 staff but may have been scored as negative by a member of the general public. In addition to this,
240 the samples tested were known positives, providing a perfect sample for the LFD. The validity of
241 self-administered tests and thus sample quality remains a concern, data published by the UK
242 government showed that LFD sensitivity was drastically reduced from 79.2% to 57.5% when LFD
243 tests were performed by members of the public compared to a trained individual¹⁵. Stories in the
244 British media suggested that false positive results can be obtained using fruit juice²⁰, something
245 which we confirmed in our laboratory. In addition, the positive control does not confirm antigen
246 detection or sample quality. This is of particular concern for self-administered tests.

247 The justification for using LFD devices is that they are rapid, cheap and can produce a result in
248 around 30 minutes whilst bypassing the requirements for rigorous laboratory standards. Our
249 streamlined laboratory PCR procedure is able to produce results in as little as 90 minutes from

250 sample receipt without the need for formal nucleic acid extraction allowing us to offer same day
251 results and our laboratory has been able to upscale to a capacity of 4000 tests a day. Whilst the cost
252 of an individual LFD device is relatively low, the actual costs to the UK tax-payers are much larger. A
253 recent audit found that of the 691 million test kits distributed, results had only been reported from
254 96 million (14%)²¹. There is no evidence of any cost-benefit analysis for LFD testing in the UK.
255 We conclude that the LFD device used in the UK has limited merit for reducing SARS-CoV-2 infection
256 in the community as it is 6000 – 10000 times less sensitive than PCR. A negative result may provide
257 a false sense of security and should be interpreted with extreme caution. It has been suggested that
258 LFD devices could be used to test individuals 7 days after a positive PCR test to confirm that their
259 viral load is low enough to allow safe release from quarantine^{7,22}. However, an ongoing transmission
260 risk may remain and a PCR test would still be more appropriate, both individually and for
261 epidemiological purposes. We believe that the use of LFD testing for SARS-CoV-2 diagnostics in the
262 UK (and globally) is a strategy which has risks that outweigh any potential benefits. Based on the
263 data presented here, it is no surprise that the US FDA has issued a Class I recall for the Innova kit,
264 citing concerns over the performance of the device²³. Innova has been issued with a warning letter
265 by the FDA relating to misleading data in the validation of the kit. Despite this, the device remains
266 approved for use in the UK (by the Medicines and Healthcare products Regulatory Agency).

267

268

269

270

271

272

273

274

275

276

277 **References**

278

279 ¹Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China:
280 a systematic review and meta-analysis. *Journal of Infection* 2020; 80:656–65.

281 ²Song Y, Liu P, Shi XL, et al. SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-
282 19. *Gut* 2020;69:1143-1144.

283 ³WHO. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational
284 Update, June 2021. ([https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)
285 [reports](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)).

286 ⁴Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time
287 RT-PCR. *Eurosurveillance* 2020;25:2000045.

288 ⁵CDC.org. Research Use Only 2019-Novel Coronavirus (2019-nCoV) Real-time RT-PCR Primer and
289 Probe Information, June 2020. ([https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-](https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html)
290 [primer-probes.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html)).

291 ⁶Calvez R, Taylor A, Calvo-Bado L, Fraser D, Fink CG. Molecular detection of SARS-CoV-2 using a
292 reagent-free approach. *PLoS ONE* 2020;15:e0243266.

293 ⁷Strömer A, Rose R, Schäfer M, et al. Performance of a Point-of-Care Test for the Rapid Detection of
294 SARS-CoV-2 Antigen. *Microorganisms* 2021;9:58.

295 ⁸Caruana G, Croxatto A, Kampouri E, Kritikos A, Opota O. Implementing SARS-CoV-2 Rapid Antigen
296 Testing in the Emergency Ward of a Swiss University Hospital: The INCREASE Study. *Microorganisms*
297 2021;7: 798.

298 ⁹Deeks JJ & Raffle AE. Lateral flow tests cannot rule out SARS-CoV-2 infection. *BMJ*
299 2020;371:m4787.

300 ¹⁰Osterman A, Baldauf HM, Eletreby M, et al. Evaluation of two rapid antigen tests to detect
301 SARS-CoV-2 in a hospital setting. *Medical Microbiology and Immunology* 2021;210: 65-72.

302 ¹¹Thommes L, Burkert FR, Öttl KW, et al (2021) Comparative evaluation of four SARS-CoV-2 antigen
303 tests in hospitalized patients. *International Journal of Infectious Disease* 2021;105: 144-6.

304 ¹²Wolf A, Hulmes J, Hopkins S. Lateral flow device specificity in phase 4 (post marketing)
305 surveillance. Department of Health & Social Care, March 2021.
306 ([https://www.gov.uk/government/publications/lateral-flow-device-specificity-in-phase-4-post-](https://www.gov.uk/government/publications/lateral-flow-device-specificity-in-phase-4-post-marketing-surveillance)
307 [marketing-surveillance](https://www.gov.uk/government/publications/lateral-flow-device-specificity-in-phase-4-post-marketing-surveillance)).

308 ¹³Homza M, Zelena H, Janosek J, et al. Covid-19 antigen testing: better than we know? A test
309 accuracy study. *Infectious Diseases* 2021;0: 1-13.

310 ¹⁴Mackay SL, Toblowsky FA, Moritz ED, et al. Performance evaluation of serial SARS-CoV-2 rapid
311 antigen testing during a nursing home outbreak. *Annals of Internal Medicine* 2021;10.7326/M21-
312 0422.

313 ¹⁵PHE (Public Health England) & University of Oxford. Preliminary report from the Joint PHE Porton
314 Down & University of Oxford SARS-CoV-2 test development and validation cell: Rapid evaluation of
315 Lateral Flow Viral Antigen detection devices (LFDs) for mass community testing, November 2020.
316 ([https://www.ox.ac.uk/sites/files/oxford/media_wysiwyg/UK%20evaluation_PHE%20Porton%20Do](https://www.ox.ac.uk/sites/files/oxford/media_wysiwyg/UK%20evaluation_PHE%20Porton%20Down%20University%20of%20Oxford_final.pdf)
317 [wn%20%20University%20of%20Oxford_final.pdf](https://www.ox.ac.uk/sites/files/oxford/media_wysiwyg/UK%20evaluation_PHE%20Porton%20Down%20University%20of%20Oxford_final.pdf)).

318 ¹⁶Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation with RT-
319 PCR cycle threshold values in cases of COVID-19, England, January to May 2020. *Eurosurveillance*
320 2020;25: 2001483.

321 ¹⁷Mytton OT, McCarthy N, Watson J, Whiting P. Interpreting a lateral flow SARS-CoV-2 antigen test.
322 *British Medical Journal* 2021;373: n1411.

323 ¹⁸University of Liverpool. Liverpool covid-19 community testing pilot interim evaluation 2020.
324 December 2020.
325 ([https://www.liverpool.ac.uk/media/livacuk/coronavirus/Liverpool,Community,Testing,Pilot,Interim,](https://www.liverpool.ac.uk/media/livacuk/coronavirus/Liverpool,Community,Testing,Pilot,Interim,Evaluation.pdf)
326 [Evaluation.pdf](https://www.liverpool.ac.uk/media/livacuk/coronavirus/Liverpool,Community,Testing,Pilot,Interim,Evaluation.pdf)).

327 ¹⁹Ladoy A, Opota O, Carron P-N, et al. Size and duration of COVID-19 clusters go along with a high
328 SARS-CoV-2 viral load: A spatio-temporal investigation in Vaud state, Switzerland. Science of the
329 Total Environment 2021; 787:147483.

330 ²⁰The Guardian (2021) UK pupils use orange juice to fake 'positive' Covid test results. July 2021.
331 ([https://www.theguardian.com/world/2021/jul/02/uk-pupils-orange-juice-fake-positive-covid-test-](https://www.theguardian.com/world/2021/jul/02/uk-pupils-orange-juice-fake-positive-covid-test-results)
332 [results](https://www.theguardian.com/world/2021/jul/02/uk-pupils-orange-juice-fake-positive-covid-test-results)).

333 ²¹Department of Health and Social Care (2021) Test and trace in England – progress update, June
334 2021. (<https://www.nao.org.uk/report/test-and-trace-in-england-progress-update/>).

335 ²²Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity — A Strategy for
336 Containment. New England Journal of Medicine 2020; 383:22.

337 ²³US FDA (2021) Stop Using Innova SARS-CoV-2 Antigen Rapid Qualitative Test: FDA Safety
338 Communication, June 2021. ([https://www.fda.gov/medical-devices/safety-communications/stop-](https://www.fda.gov/medical-devices/safety-communications/stop-using-innova-sars-cov-2-antigen-rapid-qualitative-test-fda-safety-communication)
339 [using-innova-sars-cov-2-antigen-rapid-qualitative-test-fda-safety-communication](https://www.fda.gov/medical-devices/safety-communications/stop-using-innova-sars-cov-2-antigen-rapid-qualitative-test-fda-safety-communication)).

340

341

342 **Supporting Information**

343

344 **Table S1:** Details of patient samples used for this study.

345